文献速递放疗物理与技术消化道肿瘤放疗

抑制Yes相关蛋白1诱导免疫原性细胞死亡并与放疗及PD-1阻断协同作用

Yes-Associated Protein 1 Inhibition Induces Immunogenic Cell Death and Synergizes With Radiation and PD-1 Blockade.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2023-01-04

本研究探讨抑制Yes相关蛋白1(YAP1)能否诱导免疫原性细胞死亡(ICD),以及YAP1抑制联合电离辐射(IR)能否增强体内免疫浸润并提升肿瘤对免疫治疗的反应。结果显示YAP1抑制诱导ICD并激活cGAS/STING通路,IR上调YAP1表达,YAP1抑制联合IR显著抑制肿瘤生长并延长生存,三联疗法改善胰腺癌疗效。

要点

  • YAP1抑制诱导ICD并增加抗原呈递机制水平,有效激活T细胞。
  • IR上调YAP1表达,YAP1抑制联合IR显著抑制肿瘤生长并延长生存。
  • YAP1抑制联合IR及PD-1阻断的三联疗法改善胰腺癌治疗疗效。

核心结论

  • YAP1抑制可触发ICD,是增强放疗和抗PD1免疫治疗疗效的潜在方法。

研究设计与样本

  • 本研究先检测YAP1抑制后ICD标志物、T细胞活化标志物及先天免疫信号关键蛋白的表达。
  • 随后检测不同剂量IR后YAP1蛋白表达水平。
  • 然后在体内研究YAP1抑制联合IR的抗肿瘤效应并评估肿瘤微环境免疫状态。
  • 最后确定YAP1抑制联合IR及程序性细胞死亡蛋白1阻断的三联疗法治疗耐药肿瘤的疗效。

主要发现

  • YAP1抑制诱导ICD并增加抗原呈递机制水平,有效导致T细胞活化。
  • 机制上,YAP1抑制诱导细胞DNA损伤并激活环鸟苷酸-腺苷酸合成酶(cGAS)/干扰素基因刺激因子(STING)通路。
  • IR上调YAP1表达。
  • IR联合YAP1抑制显著抑制癌症生长并延长生存,与肿瘤微环境中CD8+ T细胞浸润、活化及功能增强相关。
  • 在放疗和程序性细胞死亡蛋白1抑制剂均不理想时,加入YAP1抑制显著改善胰腺癌治疗疗效。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Danger signals released by ionizing radiation (IR) can theoretically stimulate immune activation in the tumor environment (TME), but IR alone is not sufficient to induce an effective immune response in clinical practice. In this study, we investigated whether inhibition of yes-associated protein 1 (YAP1) could induce immunogenic cell death (ICD) and whether the combination of YAP1 inhibition with IR could increase in vivo immune infiltration and thereby boost a tumor response to immunotherapy. METHODS AND MATERIALS: First, the expression of ICD markers, markers of T-cell activation, and key proteins involved in innate immune signaling were measured after YAP1 inhibition. Next, the expression level of YAP1 protein was measured after different doses of IR. Then, the antitumor effect of YAP1 inhibition combined with IR was investigated in vivo, and the immune status of the TME was evaluated. Finally, the efficacy of a triple therapy including YAP1 inhibition combined with IR and programmed cell death protein 1 blockade in the treatment of resistant tumors was determined. RESULTS: We found that YAP1 inhibition induced ICD and increased the levels of antigen presentation machinery, effectively causing the activation of T cells. Mechanistically, YAP1 inhibition induced cell DNA damage and activated the cyclic GMP-AMP synthase (cGAS)/stimulator of interferon genes (STING) pathway. Surprisingly, IR upregulated YAP1 expression. IR combined with YAP1 inhibition significantly inhibited cancer growth and prolonged survival, which was related to the augmented infiltration, activation, and function of CD8+ T cells in the TME. Moreover, the addition of YAP1 inhibition significantly improved the efficacy of pancreatic cancer treatment when neither radiation nor programmed cell death protein 1 inhibitors were ideal. CONCLUSIONS: YAP1 inhibition could trigger ICD and is a potential approach to potentiating the therapeutic efficacy of radiation therapy and anti-PD1 immunotherapy.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Zhuang Y, Wang Y, Liu C, et al. Yes-Associated Protein 1 Inhibition Induces Immunogenic Cell Death and Synergizes With Radiation and PD-1 Blockade. Int J Radiat Oncol Biol Phys. 2023. PMID: 36608830. doi:10.1016/j.ijrobp.2022.12.045

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。